Anavex Life Sciences Corp.AVXLNASDAQ
Loading
Year-over-year net income growth rate
3Y CAGR
+66.0%/yr
vs -36.6%/yr prior
Acceleration
+102.6pp
Accelerating
Percentile
P92
Near historical high
vs 3Y Ago
4.6x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 42.19% |
| Q3 2025 | 25.79% |
| Q2 2025 | -18.28% |
| Q1 2025 | 7.56% |
| Q4 2024 | -4.23% |
| Q3 2024 | 4.86% |
| Q2 2024 | -15.82% |
| Q1 2024 | -22.32% |
| Q4 2023 | 15.02% |
| Q3 2023 | 10.05% |
| Q2 2023 | 13.94% |
| Q1 2023 | -1.04% |
| Q4 2022 | 9.23% |
| Q3 2022 | -15.55% |
| Q2 2022 | -18.49% |
| Q1 2022 | 4.09% |
| Q4 2021 | 7.13% |
| Q3 2021 | -15.11% |
| Q2 2021 | -24.83% |
| Q1 2021 | -3.82% |
| Q4 2020 | -31.68% |
| Q3 2020 | 8.04% |
| Q2 2020 | 10.36% |
| Q1 2020 | -9.78% |
| Q4 2019 | -69.92% |
| Q3 2019 | 40.52% |
| Q2 2019 | 10.00% |
| Q1 2019 | -4.73% |
| Q4 2018 | -19.45% |
| Q3 2018 | -103.32% |
| Q2 2018 | 40.04% |
| Q1 2018 | -17.07% |
| Q4 2017 | 21.25% |
| Q3 2017 | -42.78% |
| Q2 2017 | -133.05% |
| Q1 2017 | 50.77% |
| Q4 2016 | 51.67% |
| Q3 2016 | -190.62% |
| Q2 2016 | -10.32% |
| Q1 2016 | 48.65% |